Latest Leadership News

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Identitii reports solid quarterly progress highlighted by a strategic new director appointment, US market expansion, and a successful $1.8 million capital raise, underpinning its path toward profitability.

ASF Group Limited reported a $1.58 million cash balance for the December 2024 quarter, highlighting ongoing investments and a director retirement that could influence its strategic direction.

Radiopharm Theranostics has secured key ethics approvals to expand its clinical trial portfolio, completed significant preclinical milestones, and raised A$8 million through a strategic placement, while maintaining its cash runway to mid-2026.

Aureka Limited has completed a transformative quarter with a $6 million recapitalisation, a strategic rebranding, and the launch of a major diamond drilling program targeting gold resources in Victoria. The company’s strengthened leadership and clean balance sheet set the stage for exploration success in 2025.

FBR Limited has successfully completed its US Demonstration Program with CRH Ventures, raising $8 million through a Share Purchase Plan and positioning itself for a significant joint venture in the US construction robotics market.

African Gold Ltd confirms a trading halt as it finalises key exploration results and navigates recent executive changes, signaling pivotal developments for its Didievi Gold Project.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

Almonty Industries has secured an exclusive offtake agreement with South Korea’s SeAH Group to supply 100% of molybdenum from its Sangdong project, underpinning financial stability and strengthening local supply chains.

Karoon Energy plans to expand its on-market share buyback program by an additional US$75 million, aiming to invest a total of US$125 million in shares by the end of 2025 amid a belief that its stock is undervalued.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Kingsgate Consolidated Limited reported a 150% increase in ore mined and a 13.4% rise in gold production for the December 2024 quarter, marking its third consecutive quarter of growth. Despite some challenges with grade control and cost guidance, the company anticipates further production and efficiency gains.